ANAmir H. Zamanipoor Najafadabadi

Amir H. Zamanipoor Najafadabadi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amir H. Zamanipoor Najafadabadi has a total of 214 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Dutch prolactinoma cohort studies: cross-sectional analysis of females focusing on the patient's perspective

    by Victoria R van Trigt, Iris C M Pelsma, Ingrid M Zandbergen, Leontine E H Bakker, Olaf M Dekkers, Amir H Zamanipoor Najafabadi, Saskia le Cessie, M Elske van Den Akker-Van Marle, Madeleine L Drent, Dirk Jan Stenvers, et al.

    Purpose: To assess the results of patient-reported outcome measures (PROMs) by disease activity in a national cohort of females with a prolactinoma. Methods: Females with prolactinoma included in the PRolaCT or ProlaC study were assessed cross-sectionally, comparing patients with active (prolactin above upper limit of normal [ULN]) and controlled (prolactin < ULN) disease. Disease and treatment characteristics were reported. Patients completed PROMs on symptoms (modified PRO-CTCAE), health-related quality of life (HR-QoL) (SF-36), anxiety and depressive symptoms (Hospital Anxiety and Depression Scale (HADS)), and disease burden (Leiden Bother and Needs Questionnaire for patients with Pituitary disease [LBNQ-Pituitary]). Results: A total of 450 females with a prolactinoma were included (active: n = 223, controlled: n = 227); most (97.0%) were treated with dopamine agonists (DAs). Fatigue was the most prevalent symptom in both patients with active and controlled disease (92.6%, and 86.4%, respectively) followed by concentration problems (79.0%, and 64.5%, respectively) (modified PRO-CTCAE, LBNQ-Pituitary). Anxiety and depressive symptoms were worse in patients with active compared to controlled disease (HADS-Anxiety: 8.0 ± 4.5 vs 6.4 ± 4.5 P < .001. HADS-Depression: 6.4 ± 5.0 vs 4.7 ± 4.4 P < .001). Disease burden was higher in patients with active compared to controlled disease (LBNQ-Pituitary: Total Bother 24.4 ± 22.9 vs 16.4 ± 17.9; P < .001). Conclusion: Females with a prolactinoma were most affected by fatigue and cognitive complaints. Although patients with active disease perceived more burden than patients with controlled disease, symptoms including fatigue and psychological and cognitive complaints were prevalent despite disease control. Therefore, improvement of treatment and rehabilitation strategies is needed.


  • Open Access

    How to Define Success in Prolactinoma Treatment—A Systematic Review and Theoretical Framework

    by Victoria R van Trigt, Kevin A Huynh, Leontine E H Bakker, Iris C M Pelsma, Ingrid M Zandbergen, Amir H Zamanipoor Najafabadi, Marco J T Verstegen, Wouter R van Furth, Nienke R Biermasz

    Purpose: As consensus regarding outcome sets for prolactinoma treatment evaluation is lacking, this study evaluated outcome parameters reported in the literature, and objective, clinically relevant outcome sets were proposed. Methods: A systematic review of studies up to February 2, 2024. Reported biochemical and radiological parameters; clinician-reported findings; patient-reported outcomes (PROs); and definitions of disease remission, control, and recurrence were extracted and placed into a clinical context. Subsequently, objective and clinically relevant definitions of clinical outcomes were proposed based on the findings, with comprehensive outcome sets to evaluate treatment success. Results: One hundred thirty-seven articles were included. Albeit ill-defined or subjective, 23 unique prolactin parameters and 73 unique radiological parameters were reported. Seventy articles included clinician-reported findings, and none reported PROs. Ultimately, 27 unique definitions of remission, 3 unique definitions of disease control, and 20 unique definitions of recurrence were reported. We propose 2 separate definitions for biochemical and clinical remission/recurrence—either evaluating prolactin levels only or including symptomology, gonadal function, and radiology. Integrated outcome quadrants were illustrated to objectively categorize treatment success by combining achievement of treatment goals with the occurrence of adverse effects. A 3-tier outcome set based on the Value-Based Healthcare principles is provided. Conclusion: Heterogeneity in reported outcome parameters using varying definitions hampers the comparison of prolactinoma treatment outcomes. This study proposes objective, easily applicable, and clinically relevant definitions of clinical outcomes and offers a comprehensive outcome set. These parameters enable comparison of outcomes across treatment modalities and medical centers to gain insight into this rare disease and improve prolactinoma care.


  • Open Access

    Recovery of Third, Fourth, and Sixth Cranial Nerve Palsies in Pituitary Adenoma and Meningioma Patients

    by Li-Pei J. Lu, Iris C. M. Pelsma, Friso de Vries, Saskia P. A. van Hulst-Ginjaar, Wouter R. van Furth, Marco J. T. Verstegen, Fleur L. Fisher, Amir H. Zamanipoor Najafadabadi, Nienke R. Biermasz, Stijn W. van der Meeren, et al.

    Background: This retrospective, observational cohort study aimed to determine recovery rate and recovery time of ocular motor nerve palsies (OMP) of third (CN III), fourth (CN IV), or sixth cranial nerves (CN VI)—and associated prognostic factors—in meningioma and pituitary adenoma (PA) patients. Methods: A total of 25 meningioma (28 eyes) and 33 PA patients (36 eyes), treated at the Leiden University Medical Center in the Netherlands from January 1, 1978 to January 31, 2021, were included. OMPs were evaluated according to a newly created recovery scale using on-clinical and orthoptic examinations, which were performed every 3–4 months until palsy recovery, or at 18 months follow-up. Results: Recovery rates of CN III (meningioma 23.5% vs PA 92.3%), CN IV (meningioma 20% vs PA 100%), and CN VI (meningioma 60% vs PA 100%) palsies were observed at 18 months follow-up, with differences between the 2 tumor types being observed in the treated patients only. Median recovery time of all OMPs combined was significantly longer in meningioma patients (37.9 ± 14.3 months vs 3.3 ± 0.1 months; P < 0.001). No significant protective or risk factors for recovery rate or time were identified. Conclusions: OMP recovery rates in treated patients were more favorable in patients with PA compared with patients with meningiomas, independent of OMP cause. With these new insights in OMP recovery, more accurate prognoses and appropriate follow-up strategies can be determined for meningioma and PA patients with OMPs.


  • Health-Related Quality of Life in Intracranial Meningioma: Current Evidence and Future Directions

    by Amir H. Zamanipoor Najafabadi, Linda Dirven, Katharine J. Drummond, Martin J. B. Taphoorn

    Historically, largely due to the good prognosis for survival, there has been little attention paid to the possible impact of meningiomas and their treatment on health-related quality of life (HRQoL). However, in the last decade there has been increasing evidence that patients with intracranial meningiomas suffer from long-term decreases in their HRQoL. Compared with controls and normative data, meningioma patients have worse HRQoL scores both before and after intervention and continuing long term (even after >4 years of follow-up). Overall, surgery results in improvements in many aspects of HRQoL. The limited available studies investigating the impact of radiotherapy suggest that this type of treatment decreases HRQoL scores, especially in the long term. There is however only limited evidence on additional determinants of HRQoL. Patients with anatomically complex skull base meningiomas and severe comorbidities, including epilepsy, report the lowest HRQoL scores. Other tumor and sociodemographic characteristics have shown weak associations with HRQoL. Furthermore, about one-third of caregivers of meningioma patients report caregiver burden, warranting interventions to improve caregiver HRQoL. As antitumor interventions may not improve HRQoL scores to be comparable to those of the general population, more attention should be paid to the development of integrative rehabilitation and supportive care programs for meningioma patients. Keywords Meningioma Health-related quality of life Caregivers Surgery Determinants


  • Open Access

    Healthcare utilization and costs among intracranial meningioma patients during long-term follow-up

    by Kevin A. Huynh, Eva C. Coopmans, Amir H. Zamanipoor Najafabadi, Linda Dirven, Saskia M. Peerdeman, Nienke R. Biermasz, Marco J. T. Verstegen, Wouter R. van Furth, the Dutch Meningioma Consortium, Florien W. Boele, et al.

    Purpose: Few studies have reported on healthcare utilization and costs for intracranial meningioma patients, while the tumor and its treatment profoundly affect patients’ functioning and well-being. Here we evaluated healthcare utilization and costs, including their determinants. Methods: A multicenter cross-sectional study of adult meningioma patients ≥ 5 years after intervention. Patients completed three validated patient-reported outcome measures (PROMs) assessing patients ‘functioning and wellbeing (SF-36, EORTC QLQ-BN20, and HADS) and a study-specific questionnaire assessing healthcare utilization over the previous twelve months. Healthcare costs of the twelve months prior were calculated using reported healthcare utilization ≥ 5 years after intervention by the Dutch Manual for Economic Evaluation in Healthcare. Determinants for healthcare utilization and costs were determined with regression analyses. Results: We included 190 patients with WHO grade I or II meningioma after a mean follow-up since intervention of 9.2 years (SD 4.0). The general practitioner (80.5%), physiotherapist (37.9%), and neurologist (25.4%) were visited most often by patients. Median annual healthcare costs were €871 (IQR €262–€1933). Main contributors to these costs were medication (45.8% of total costs, of which anti-seizure medication was utilized most [21.6%]), specialist care (17.7%), and physiotherapy (15.5%). Lower HRQoL was a significant determinant for higher healthcare utilization and costs. Conclusion: In patients with meningioma, medication costs constituted the largest expenditure of total healthcare costs, in particular anti-seizure medication. Particularly a lower HRQoL was a determinant for healthcare utilization and costs. A patient-specific approach aimed at improving patients’ HRQoL and needs could be beneficial in reducing disease burden and functional recovery.


  • Open Access

    The prevalence and severity of fatigue in meningioma patients and its association with patient-, tumor- and treatment-related factors

    by Kwong T Quach, Linda Dirven, Aliede M Vingerhoed, Jeroen de Bresser, Ruben Dammers, Eelke M Bos, Wouter A Moojen, Wilco C Peul, Martin J B Taphoorn, Amir H Zamanipoor Najafabadi, et al.

    Background: Fatigue is a commonly reported and severe symptom in primary brain tumor patients, but the exact occurrence in meningioma patients is unknown. This study aimed to determine the frequency and severity of fatigue in meningioma patients as well as associations between the level of fatigue and patient-, tumor-, and treatment-related factors.Methods: In this multicenter cross-sectional study, meningioma patients completed questionnaires on fatigue (MFI-20), sleep (PSQI), anxiety and depression (HADS), tumor-related symptoms (MDASI-BT), and cognitive functioning (MOS-CFS). Multivariable regression models were used to evaluate the independent association between fatigue and each patient-, tumor-, and treatment-related factor separately, corrected for relevant confounders.Results: Based on predetermined in- and exclusion criteria, 275 patients, on average 5.3 (SD = 2.0) year since diagnosis, were recruited. Most patients had undergone resection (92%). Meningioma patients reported higher scores on all fatigue subscales compared to normative data and 26% were classified as fatigued. Having experienced a complication due to resection (OR 3.6, 95% CI: 1.8–7.0), having received radiotherapy (OR 2.4, 95% CI: 1.2–4.8), a higher number of comorbidities (OR 1.6, 95% CI: 1.3–1.9) and lower educational level (low level as reference; high level OR 0.3, 95% CI: 0.2–0.7) were independently associated with more fatigue.Conclusions: Fatigue is a frequent problem in meningioma patients even many years after treatment. Both patient- and treatment-related factors were determinants of fatigue, with the treatment-related factors being the most likely target for intervention in this patient population.


  • Open Access

    Correction to: Healthcare utilization and costs among intracranial meningioma patients during long-term follow-up

    by Kevin A. Huynh, Eva C. Coopmans, Amir H. Zamanipoor Najafabadi, Linda Dirven, Saskia M. Peerdeman, Nienke R. Biermasz, Marco J. T. Verstegen, Wouter R. van Furth, the Dutch Meningioma Consortium, Florien W. Boele, et al.

  • Open Access

    Starting point for benchmarking outcomes and reporting of pituitary adenoma surgery within the European Reference Network on Rare Endocrine Conditions (Endo-ERN): results from a meta-analysis and survey study

    by Amir H Zamanipoor Najafabadi, Merel van der Meulen, Ana Luisa Priego Zurita, S Faisal Ahmed, Wouter R van Furth, Evangelia Charmandari, Olaf Hiort, Alberto M Pereira, Mehul Dattani, Diana Vitali, et al.

    Objective: The European Reference Network on Rare Endocrine Conditions (Endo-ERN) aims to organize high-quality healthcare throughout Europe, including care for pituitary adenoma patients. As surgery is the mainstay of treatment, we aimed to describe the current surgical practice and published surgical outcomes of pituitary adenoma within Endo-ERN. Design and Methods: Systematic review and meta-analysis of studies reporting surgical outcomes of pituitary adenoma patients within Endo-ERN MTG6 pituitary reference centers between 2010 and 2019. A survey was completed by reference centers on their current surgical practice. Results: A total of 18 out of 43 (42%) reference centers located in 7 of the 20 (35%) MTG6-represented countries published 48 articles. Remission rates were 50% (95% CI: 42–59) for patients with acromegaly, 68% (95% CI: 60–75) for Cushing’s disease, and 53% (95% CI: 39–66%) for prolactinoma. Gross total resection was achieved in 49% (95% CI: 37–61%) of patients and visual improvement in 78% (95% CI: 68–87). Mortality, hemorrhage, and carotid injury occurred in less than 1% of patients. New-onset hypopituitarism occurred in 16% (95% CI: 11–23), transient diabetes insipidus in 12% (95% CI: 6–21), permanent diabetes insipidus in 4% (95% CI: 3–6), syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in 9% (95% CI: 5–14), severe epistaxis in 2% (95% CI: 0–4), and cerebrospinal fluid leak in 4% (95% CI: 2–6). Thirty-five (81%) centers completed the survey: 54% were operated endoscopically and 57% were together with an ENT surgeon. Conclusion: The results of this study could be used as a first benchmark for the outcomes of pituitary adenoma surgery within Endo-ERN. However, the heterogeneity between studies in the reporting of outcomes hampers comparability and warrants outcome collection through registries.


  • Open Access

    Meningioma systematic reviews and meta-analyses: an assessment of reporting and methodological quality

    by Alan M. George, Shubhi Gupta, Sumirat M. Keshwara, Mohammad A. Mustafa, Conor S. Gillespie, George E. Richardson, Amy C. Steele, Amir H. Zamanipoor Najafabadi, Linda Dirven, Anthony G. Marson, et al.

    Systematic reviews (SR) and systematic reviews with meta-analysis (SRMA) can constitute the highest level of research evidence. Such evidence syntheses are relied upon heavily to inform the clinica...


  • Open Access

    Development of ‘Core Outcome Sets’ for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings

    by Christopher P Millward, Terri S Armstrong, Heather Barrington, Sabrina Bell, Andrew R Brodbelt, Helen Bulbeck, Anna Crofton, Linda Dirven, Theo Georgious, Paul L Grundy, et al.

    Introduction Meningioma is the most common primary intracranial tumour in adults. The majority are non-malignant, but a proportion behave more aggressively. Incidental/minimally symptomatic meningioma are often managed by serial imaging. Symptomatic meningioma, those that threaten neurovascular structures, or demonstrate radiological growth, are usually resected as first-line management strategy. For patients in poor clinical condition, or with inoperable, residual or recurrent disease, radiotherapy is often used as primary or adjuvant treatment. Effective pharmacotherapy treatments do not currently exist. There is heterogeneity in the outcomes measured and reported in meningioma clinical studies. Two ‘Core Outcome Sets’ (COS) will be developed: (COSMIC: Intervention) for use in meningioma clinical effectiveness trials and (COSMIC: Observation) for use in clinical studies of incidental/untreated meningioma. Methods and analysis Two systematic literature reviews and trial registry searches will identify outcomes measured and reported in published and ongoing (1) meningioma clinical effectiveness trials, and (2) clinical studies of incidental/untreated meningioma. Outcomes include those that are clinician reported, patient reported, caregiver reported and based on objective tests (eg, neurocognitive tests), as well as measures of progression and survival. Outcomes will be deduplicated and categorised to generate two long lists. The two long lists will be prioritised through two, two-round, international, modified eDelphi surveys including patients with meningioma, healthcare professionals, researchers and those in caring/supporting roles. The two final COS will be ratified through two 1-day online consensus meetings, with representation from all stakeholder groups. Ethics and dissemination Institutional review board (University of Liverpool) approval was obtained for the conduct of this study. Participant eConsent will be obtained prior to participation in the eDelphi surveys and consensus meetings. The two systematic literature reviews and two final COS will be published and freely available. Trial registration number COMET study ID 1508